应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
KARD Kardigan
休市中 07-17 16:00:00 EDT
21.13
+0.11
+0.52%
盘后
21.13
+0.00
0.00%
19:24 EDT
最高
22.66
最低
19.83
成交量
41.34万
今开
20.54
昨收
21.02
日振幅
13.45%
总市值
18.53亿
流通市值
4.93亿
总股本
8,767万
成交额
874.82万
换手率
1.77%
流通股本
2,333万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Kardigan盘前下跌9%,IPO首日大涨后回调承压
行情直击 · 06-22
异动解读|Kardigan盘前下跌9%,IPO首日大涨后回调承压
生物医药企业Kardigan美股上市:市值19亿美元 路演PPT曝光
雷递网 · 06-20
生物医药企业Kardigan美股上市:市值19亿美元 路演PPT曝光
异动解读|Kardigan盘中上涨42.28%,IPO首日获市场热捧
行情直击 · 06-19
异动解读|Kardigan盘中上涨42.28%,IPO首日获市场热捧
异动解读 | 卡迪根IPO首日盘中大涨5.44%,募资4亿美元推动股价上扬
异动解读 · 06-19
异动解读 | 卡迪根IPO首日盘中大涨5.44%,募资4亿美元推动股价上扬
美股异动 | Kardigan(KARD.US)登陆美股市场 开盘涨超25%
智通财经 · 06-19
美股异动 | Kardigan(KARD.US)登陆美股市场 开盘涨超25%
加载更多
公司概况
公司名称:
Kardigan
所属市场:
NASDAQ
上市日期:
--
主营业务:
Kardigan, Inc.于2023年8月根据特拉华州法律注册成立。该公司是一家临床阶段的精准治疗公司,致力于开发针对特定心血管疾病根本病因的药物,这些疾病目前尚无获批疗法。公司的使命是并行开发多种靶向心血管疗法,使心血管疾病患者早日获得应有的治愈。公司目前有三个处于后期临床开发阶段的项目:Danicamtiv、Ataciguat和Tonlamarsen,这些项目针对的适应症目前尚无获批疗法。管理团队拥有深厚的心血管疾病领域知识,并运用创新的药物开发方法,结合公司专有的 Prolaio 平台的数据和分析技术,以高效执行的方式快速交付成果。公司在心血管药物开发中秉持高度精准的理念,着眼于疾病的根本原因,而非后期出现的心血管症状。
发行价格:
--
{"stockData":{"symbol":"KARD","market":"US","secType":"STK","nameCN":"Kardigan","latestPrice":21.13,"timestamp":1784318400000,"preClose":21.02,"halted":0,"volume":413363,"hourTrading":{"tag":"盘后","latestPrice":21.13,"preClose":21.13,"latestTime":"19:24 EDT","volume":3474,"amount":73415.76,"timestamp":1784330651252,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0052331113225499255,"floatShares":23333300,"shares":87672455,"eps":-2.623,"marketStatus":"休市中","change":0.11,"latestTime":"07-17 16:00:00 EDT","open":20.54,"high":22.66,"low":19.8325,"amount":8748188.835802,"amplitude":0.134515,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.623,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784534400000},"marketStatusCode":7,"adr":0,"listingDate":1781755200000,"exchange":"NASDAQ","adjPreClose":21.02,"preHourTrading":{"tag":"盘前","latestPrice":20.96,"preClose":21.02,"latestTime":"09:28 EDT","volume":143,"amount":3051.240049,"timestamp":1784294880121,"change":-0.06,"changeRate":-0.002854,"amplitude":0.020932},"postHourTrading":{"tag":"盘后","latestPrice":21.13,"preClose":21.13,"latestTime":"19:24 EDT","volume":3474,"amount":73415.76,"timestamp":1784330651252,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1782813109274637},"requestUrl":"/m/hq/s/KARD","defaultTab":"news","newsList":[{"id":"1174474370","title":"异动解读|Kardigan盘前下跌9%,IPO首日大涨后回调承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1174474370","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174474370?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:15","pubTimestamp":1782134146,"startTime":"0","endTime":"0","summary":"6月22日,Kardigan盘前下跌9%,报20.02美元/股,成交额41.49万美元。消息面上,该股于6月19日以每股16美元的发行价登陆纳斯达克,IPO首日涨幅超42%,募资约4亿美元,定价位于发行区间上限。IPO交割预计于6月22日完成,经历首日大幅上涨后盘前出现回调。Kardigan是一家临床阶段精准心血管疗法公司,旗下拥有Danicamtiv、Ataciguat及Tonlamarsen三项后期临床管线,均聚焦当前尚无获批疗法的心血管适应症,目前尚未实现商业化收入。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644206089","title":"生物医药企业Kardigan美股上市:市值19亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2644206089","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644206089?lang=zh_cn&edition=full","pubTime":"2026-06-20 18:30","pubTimestamp":1781951405,"startTime":"0","endTime":"0","summary":"美国心血管生物医药企业Kardigan(股票代码:“KARD”)日前在美国纳斯达克上市,发行价为16美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260620/6391757686513187695524647.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260620/6391757686513187695524647.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34089/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4581","XBI","161726","IPOS","PPT","KARD","BK4585","399441","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123564483","title":"异动解读|Kardigan盘中上涨42.28%,IPO首日获市场热捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1123564483","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123564483?lang=zh_cn&edition=full","pubTime":"2026-06-19 03:47","pubTimestamp":1781812023,"startTime":"0","endTime":"0","summary":"6月19日,Kardigan盘中上涨42.28%,报22.765美元/股,成交额9976.32万美元。消息面上,Kardigan于当日正式登陆纳斯达克市场,以每股16美元的价格发行2500万股,募资约4亿美元,定价位于此前14至16美元发行区间上限,并授予承销商30天内超额配售375万股的选择权。首日交易中股价最高触及21美元上方,市场追捧情绪显著。Kardigan是一家临床阶段精准心血管疗法公司,旗下拥有Danicamtiv、Ataciguat及Tonlamarsen三项后期临床管线,均聚焦当前尚无获批疗法的心血管适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115903126","title":"异动解读 | 卡迪根IPO首日盘中大涨5.44%,募资4亿美元推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1115903126","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115903126?lang=zh_cn&edition=full","pubTime":"2026-06-19 00:41","pubTimestamp":1781800867,"startTime":"0","endTime":"0","summary":"生物科技公司卡迪根今日盘中大涨5.44%,引起了市场的广泛关注。消息面上,卡迪根成功完成了规模扩大的首次公开募股,以每股16美元的价格发行2500万股,共筹集4亿美元资金,发行价位于目标区间上限。该公司股票于今日在纳斯达克交易所首次上市交易,市场对其首日表现抱有较高期待。公司计划将本次IPO募集资金用于这些药物的临床开发及其他研发活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644708021","title":"美股异动 | Kardigan(KARD.US)登陆美股市场 开盘涨超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644708021","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644708021?lang=zh_cn&edition=full","pubTime":"2026-06-19 00:00","pubTimestamp":1781798400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周四,Kardigan(KARD.US)登陆美股市场,开盘股价涨超25%,报20.1美元。IPO价格为16美元。Kardigan是一家专注于心血管疾病创新疗法研发的临床阶段生物技术公司,致力于开发用于治疗心律失常及其他心脏疾病的新一代精准药物。公司核心产品管线聚焦于调节心脏电生理功能,通过靶向特定离子通道改善异常心律问题,目标是在提升疗效的同时降低传统抗心律失常药物带来的安全性风险。目前,公司多项候选药物仍处于临床开发阶段,尚未实现商业化收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | Kardigan(KARD.US)登陆美股市场 开盘涨超25%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KARD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kardigan.bio","stockEarnings":[{"period":"1week","weight":-0.1423},{"period":"1month","weight":0.3206},{"period":"ytd","weight":0.3206}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kardigan, Inc.于2023年8月根据特拉华州法律注册成立。该公司是一家临床阶段的精准治疗公司,致力于开发针对特定心血管疾病根本病因的药物,这些疾病目前尚无获批疗法。公司的使命是并行开发多种靶向心血管疗法,使心血管疾病患者早日获得应有的治愈。公司目前有三个处于后期临床开发阶段的项目:Danicamtiv、Ataciguat和Tonlamarsen,这些项目针对的适应症目前尚无获批疗法。管理团队拥有深厚的心血管疾病领域知识,并运用创新的药物开发方法,结合公司专有的 Prolaio 平台的数据和分析技术,以高效执行的方式快速交付成果。公司在心血管药物开发中秉持高度精准的理念,着眼于疾病的根本原因,而非后期出现的心血管症状。","exchange":"NASDAQ","name":"Kardigan","nameEN":"Kardigan"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kardigan(KARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kardigan(KARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kardigan,KARD,Kardigan股票,Kardigan股票老虎,Kardigan股票老虎国际,Kardigan行情,Kardigan股票行情,Kardigan股价,Kardigan股市,Kardigan股票价格,Kardigan股票交易,Kardigan股票购买,Kardigan股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kardigan(KARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kardigan(KARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}